跳至主要内容
临床试验/TCTR20230426007
TCTR20230426007已完成4 期

The Accuracy and Feasibility of Continuous Glucose Monitoring in COVID-19 Non-Critically Ill Hospitalized Patients: A Pilot Study

Specific League Funds0 个研究点目标入组 15 人开始时间: 2023年4月26日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
15

研究概览

简要总结

Rt CGM use in hospitalized patients with COVID 19 infection demonstrates high accuracy and potentially improves glucose control, reduces the frequency of CBG testing, and preserves medical resources.

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. Hospitalized patients 18 years old of age or older
  • 2. Positive COVID-19 RT-PCR test
  • 3. Hyperglycemia requiring insulin therapy during admission in non-ICU units 4. Capability to use rt-CGMs and perform self-monitoring of CBG

排除标准

  • 1. Coagulopathy (INR over 3)
  • 2. Thrombocytopenia (platelet count less than 20,000/uL)
  • 3. Hypotension (defined as BP less than 90/60 mmHg) or poor tissue perfusion
  • 4. Multiorgan failure
  • 5. Significant edema
  • 6. Current treatment with dual antiplatelet therapy or medications known to interfere with the accuracy of CGMs such as hydroxyurea, intravenous ascorbic acid, paracetamol more than 4 grams in 24 hours

研究者

发起方
Specific League Funds

相似试验